Charles Schwab Investment Management Inc Cyclerion Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$0.96 - $1.78 $14,876 - $27,582	-15,496 Closed	0 $0
Q3 2021 Nov 16, 2021	SELL	$2.73 - $4.13 $311,580 - $471,365	-114,132 Reduced 88.05%	15,496 $48,000
Q2 2021 Aug 16, 2021	SELL	$2.18 - $4.29 $152,706 - $300,510	-70,049 Reduced 35.08%	129,628 $506,000
Q1 2021 May 17, 2021	BUY	$2.69 - $5.12 $60,756 - $115,640	22,586 Added 12.75%	199,677 $558,000
Q4 2020 Feb 16, 2021	SELL	$2.25 - $7.12 $27,724 - $87,732	-12,322 Reduced 6.51%	177,091 $542,000
Q3 2020 Nov 13, 2020	BUY	$3.46 - $8.39 $206,382 - $500,446	59,648 Added 45.97%	189,413 $1.15 Million
Q2 2020 Aug 14, 2020	BUY	$2.37 - $7.14 $54,332 - $163,684	22,925 Added 21.46%	129,765 $767,000
Q1 2020 May 15, 2020	BUY	$2.46 - $5.84 $3,461 - $8,216	1,407 Added 1.33%	106,840 $284,000
Q4 2019 Feb 07, 2020	SELL	$1.8 - $13.43 $12,918 - $96,387	-7,177 Reduced 6.37%	105,433 $287,000
Q3 2019 Nov 08, 2019	BUY	$8.12 - $14.54 $105,332 - $188,612	12,972 Added 13.02%	112,610 $1.37 Million
Q2 2019 Aug 09, 2019	BUY	$9.6 - $22.85 $956,524 - $2.28 Million	99,638 New	99,638 $1.14 Million

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $139M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.